SCHEMBL2649947

SCHEMBL2649947

O=Cc1ccc(C(=O)O)c2ccccc12

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR4A1 P22736 1/20 0.48
NR4A2 P43354 1/20 0.48
NR4A3 Q92570 1/20 0.48
WDR5 P61964 1/20 0.46
ALDH1A1 P00352 1/20 0.44
ALOX15 P16050 1/20 0.44
KDM4E B2RXH2 5/20 0.44
LDHA P00338 1/20 0.44
CYP2C9 P11712 1/20 0.44
HPGD P15428 1/20 0.44
TSHR P16473 1/20 0.44
ALOX12 P18054 1/20 0.44
ATIC P31939 1/20 0.44
HSD17B10 Q99714 1/20 0.44
THRB P10828 2/20 0.41
MEN1 O00255 2/20 0.41
LMNA P02545 2/20 0.41
KMT2A Q03164 2/20 0.41
BLM P54132 1/20 0.41
TDP1 Q9NUW8 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29957209 1.00 NR4A1 (0.48) NR4A1NR4A2NR4A3WDR5ALDH1A1
SCHEMBL7537971 0.88 NR4A1 (0.53) NR4A1NR4A2NR4A3ALDH1A1ALOX15
SCHEMBL28798 0.82 NR4A1 (0.65) NR4A1NR4A2NR4A3WDR5ALDH1A1
SCHEMBL29406630 0.82 NR4A1 (0.65) NR4A1NR4A2NR4A3WDR5ALDH1A1
SCHEMBL30838413 0.82 NR4A1 (0.65) NR4A1NR4A2NR4A3WDR5ALDH1A1
SCHEMBL30838412 0.82 NR4A1 (0.65) NR4A1NR4A2NR4A3WDR5ALDH1A1
SCHEMBL23528851 0.82 ALDH1A1 (0.39) ALDH1A1ALOX15KDM4ETSHRTHRB
SCHEMBL7195362 0.82 NR4A1 (0.47) NR4A1NR4A2NR4A3WDR5ALDH1A1
SCHEMBL31518427 0.82 NR4A1 (0.47) NR4A1NR4A2NR4A3WDR5ALDH1A1
SCHEMBL1506782 0.82 NR4A1 (0.47) NR4A1NR4A2NR4A3WDR5ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118852045-A Preparation method of rana medicine 河北圣雪大成制药有限责任公司 2024-10-29 CN claimed
CN-114456059-B Method for preparing aforana intermediate 丽珠集团新北江制药股份有限公司 2024-01-02 CN claimed
CN-114113388-B Method for detecting related substances in 4-oxime methyl-1-naphthoic acid 丽珠集团新北江制药股份有限公司 2023-05-23 CN claimed
CN-114456059-A Method for preparing Aforana intermediate 丽珠集团新北江制药股份有限公司 2022-05-10 CN claimed
CN-114113388-A Method for detecting related substances in 4-oximinomethyl-1-naphthoic acid 丽珠集团新北江制药股份有限公司 2022-03-01 CN claimed
CN-112679338-A Method for preparing oxazoline insecticide alfilana intermediate 丽珠集团新北江制药股份有限公司 2021-04-20 CN claimed
US-20260070879-A1 ISOXAZOLINE DERIVATIVES ELANCO TIERGESUNDHEIT AG (CH) 2026-03-12 US disclosed
US-12497370-B2 Isoxazoline derivatives ELANCO TIERGESUNDHEIT AG (CH) 2025-12-16 US disclosed
CN-120004816-A Isoxazoline derivatives 礼蓝动物保健有限公司 2025-05-16 CN disclosed
CN-115210221-B Isoxazoline derivatives as pesticides 礼蓝动物保健有限公司 2025-03-18 CN disclosed
CN-118852045-A Preparation method of rana medicine 河北圣雪大成制药有限责任公司 2024-10-29 CN disclosed
CN-118852045-A Preparation method of rana medicine 河北圣雪大成制药有限责任公司 2024-10-29 CN disclosed
CN-118146085-A Treatment method for material ending in middle of reaction for preparing 1, 4-naphthalene dicarboxylic acid by oxidizing 1-methyl-4-naphthalene carboxylic acid by oxygen 黄石市利福达医药化工有限公司 2024-06-07 CN disclosed
WO-2002005646-A2 COMPOSITIONS FOR REPELLING CRAWLING INSECTS S.C. JOHNSON & SON, INC. (US) (US) 2002-01-24 WO disclosed
EP-0994848-A1 GLUCAGON ANTAGONISTS/INVERSE AGONISTS NOVO NORDISK A/S (DK) 2000-04-26 EP disclosed
WO-1999001423-A1 GLUCAGON ANTAGONISTS/INVERSE AGONISTS NOVO NORDISK A/S (DK) 1999-01-14 WO disclosed
WO-1999001423-A1 GLUCAGON ANTAGONISTS/INVERSE AGONISTS NOVO NORDISK A/S (DK) 1999-01-14 WO disclosed
US-4016195-A OPTICAL BRIGHTENERS HOECHST AKTIENGESELLSCHAFT (DT) 1977-04-05 US disclosed
US-4000275-A BENZIMIDAZO(2,1-B) QUINAZOLIN-12(6H)ONES ELI LILLY AND COMPANY (US) 1976-12-28 US disclosed
US-3957846-A OPTICAL BRIGHTENERS, LACQUERS, SYNTHETIC FIBERS HOECHST AKTIENGESELLSCHAFT (DT) 1976-05-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12497370-B2 Isoxazoline derivatives CYP3A7, CYP4X1, CYP2A7 NR4A1 1679/4885NR4A2 1867/4885NR4A3 1908/4885
US-20260070879-A1 ISOXAZOLINE DERIVATIVES CHRM1, CBR3, AFF1 NR4A1 287/4885NR4A2 827/4885NR4A3 643/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.